Mitomycin C

Mitomycin C is a cell cycle-phase nonspecific antineoplastic. Mitomycin is a natural product obtained from Streptomyces caespitosus and is used in the treatment of stomach, pancreatic, breast, colon, head, neck, and lung cancers. Adenocarcinomas of the gastrointestinal tract are particularly sensitive. Mitomycin is an atypical alkylating agent. Mitomycin C is unique for its delayed and deep myelosuppression. There are no other drugs similar to mitomycin on the market. Mitomycin is sometimes referred to as MMC or mitomycin C. Mitomycin was approved by the FDA in 1974. Mitomycin must be metabolized by hepatic microsomal enzymes to be active. The metabolite is an alkylating agent that binds to DNA. RNA usually is not affected. Mitomycin is also capable of creating oxygen free radicals, which damage DNA. The alkylating activity, however, causes the most damage. Both mechanisms lead to interference in DNA replication, transcription of RNA, and nucleic acid function, and both activities contribute to cell death.

Brands

MITOMYCIN MITOMYCIN MITOCIN MITOMYCIN-C MITOMYCIN-C

Adult Dose

Dose: 10 to 20 mg/sq.metre
Single Dose: 15 (15)
Frequency: As recommended.
Route: IV Inf
Instructions: Every 4 to 6 weeks

Neonatal

Paedriatic

Characteristics

. It is of Natural origin and belongs to Quinone. It belongs to Cross Linkage (DNA acting) pharmacological group on the basis of mechanism of action and also classified in Antineoplastic Agent, Antibiotic pharmacological group.The Molecular Weight of Mitomycin C is 334.30.

Contraindications

Mitomycin C is contraindicated in conditions like Myelosuppression.

Effects

The severe or irreversible adverse effects of Mitomycin C, which give rise to further complications include Renal damage, Thrombocytopenia, Leucopenia, Diffused pulmonary infiltration.Mitomycin C produces potentially life-threatening effects which include Bone marrow, Suppression, Hemolytic anemia, Hemolytic anemia. which are responsible for the discontinuation of Mitomycin C therapy.The signs and symptoms that are produced after the acute overdosage of Mitomycin C include Severe myelosuppression.The symptomatic adverse reactions produced by Mitomycin C are more or less tolerable and if they become severe, they can be treated symptomatically, these include Alopecia, Diarrhea, Stomatitis, Nausea and vomiting, Alopecia, Cellulitis.

Indications

Mitomycin C is primarily indicated in conditions like Bladder carcinoma, Breast cancer, Cervical carcinoma, Lung cancer, Stomach cancer, Upper gastro-intestinal and breast cancer, and can also be given in adjunctive therapy as an alternative drug of choice in Colon tumor, Pancreatic tumour, Pancreatic tumour, Soft tissue sarcoma.

Interactions

Mitomycin C is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCimetidine (HCl)DextromethorphanFluorouracilSulfapyridineConcurrent use of sulfapyridine with bone marrow depressants may increase the leukopenic or thrombocytopenic effects of these medications.If concurrent use is required, close observation for myelotoxic effects should be considered.Vinblastine (Sulphate)Vincristine (Sulphate) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Interfrence

Risks

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Storage

Inj (reconstituted soln) Store at room temperature or refrigerator. Protect from Sunlight. Use within 2 weeks if refrigerated and within 1 week if kept at room temperature.

Warnings

Mitomycin C must not be used during pregnancy or lactation. It should be used with caution in patients with any pre-existing blood disorder, kidney disease or any allergy.

Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.